In Conversation with Anne Le, M.D, H.D.R., Founder and CEO of Gigantest

Published on :

Serving as a professor at Johns Hopkins for over a decade, Dr. Le recently decided to step out of her comfort zone and start her own company in Baltimore’s Inner Harbor, Gigantest, which provides next-level metabolomics services for scientists and physicians at leading institutions around the world.

In Conversation: Barry Wells, MD, Director of Business Development, American Gene TechnologiesⓇ

Barry Wells
Published on :

Rockville, Maryland’s American Gene Technologies (AGT™) HIV cure program has been making remarkable progress in its mission to bring a single-dose cure to people living with HIV. That mission is steadily advancing through a successful Phase 1 human clinical trial. The company hopes to begin its Phase 2 study during 2023; this could yield very compelling data towards a functional cure, occurring perhaps as early as the first half of 2024.

In Conversation: Sunitha Venkatanarayanan, Practice Lead, Data Science and Insights at Conexus Solutions

Conexus Solutions, Inc.
Published on :

We recently spoke with Sunitha Venkatanarayanan, Conexus’ Practice Lead (Data Science & Insights), about her own career journey, the power of data science, and what the company has to offer small to midsize pharma and life sciences companies. 

In Conversation: Justin Amoyal, CEO and Co-founder, Impruvon Health

Justin Amoyal Impruvon Health
Published on :

Impruvon Health’s (Impruvon) mission to build and deploy a smarter, scalable enterprise medication workflow management platform is personal for Founder and CEO Justin Amoyal—he tragically lost his brother in 2019 to an accidental drug overdose caused by a process that is too manual and highly susceptible to human error.  

In Conversation: Trushar Agrawal, Senior Director and Head of Manufacturing at Kite Pharma

Published on :

This past summer, Kite promoted biotech industry veteran Trushar Agrawal from his Director of QA role to Senior Director, Head of Manufacturing for the Frederick site. Agrawal will work to bring on new team members as the site ramps up commercial production of its CAR T-cell therapy product, which is used to treat people living with blood cancer. 

In Conversation: Dr. Amrie Grammer, Co-founder, President and Chief Scientific Officer, AMPEL Biosolutions

Amrie Grammer
Published on :

AMPEL Biosolutions (AMPEL), located in Charlottesville, Virginia is a leading personalized precision medicine company developing tools that can help autoimmune and inflammatory disease patients improve their quality of life. AMPEL is one of the exciting companies that have emerged from the Charlottesville (CVille) biohub clustered around the University of Virginia (UVA). 

In Conversation: Maria Lopez, General Manager, U.S. Cell Therapy at Catalent Biologics

Published on :

Catalent Biologics (Catalent), a global contract development and manufacturing organization (CDMO), is a leader in providing comprehensive solutions for life sciences companies of all sizes. Catalent’s 19,000+ employees and approximately 2,500 scientists partner with pharma, biotech, and consumer health companies to optimize product development, launch, and full life-cycle supply for patients around the world. 

In Conversation: Ken Malone, Ph.D., Managing Director, Early Charm Ventures and CEO of SilcsBio

Published on :

Malone is the Managing Director of Early Charm and the CEO of SilcsBio, one of the 37 portfolio companies that operate under Early Charm’s novel Venture Studio Model. We recently caught up with Malone to discuss a wide range of topics, including the Venture Studio Model, SilcsBio, and the growing life sciences and technology ecosystem blooming in Baltimore. 

In Conversation: Rodeina Challand, VP Scientific Affairs, BioFactura

Published on :

A key recent hire at Frederick-based BioFactura was biosimilars and scientific affairs expert Rodeina Challand, who joined the BioFactura team as its new VP of Scientific Affairs in late 2021. We caught up with Challand to discuss her background, the biosimilars market landscape, and why she’s excited about what’s next for BioFactura. 

In Conversation: Jeff Boyle, Chief Science Officer at American Gene Technologies

Published on :

American Gene Technologies recently named Dr. Jeff Boyle as its new Chief Science Officer. Boyle was previously President at Ellume USA where he led the build out of the company’s 180,000 square foot manufacturing facility in Frederick, Maryland that produces the first COVID-19 home self-test to receive an EUA from the FDA.